RxDoctor Payments Data

Valerie Lavallee, PA

Surgical · Manchester, NHNPI 1306855937

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 41.5% of the total.

$714in general payments, 2019–2025

Across 15 payments — averaging $47.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$296
  • Teleflex LLC$141
  • Medtronic$126
  • Cycle Pharmaceuticals Inc$30
  • C. R. Bard, Inc. & Subsidiaries$29
  • Convatec Inc.$28
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$714 in reported general payments places this provider in the 60th percentile of 86 surgical providers in New Hampshire.

See all surgical providers in New Hampshire

Medicare billing

Part B allowed, 2024
$44,650
Medicare patients
309
Services billed
1,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron274$181,974
GemtesaVibegron61$49,964
Tamsulosin Hcl802$10,879
Solifenacin Succinate175$9,369
Mirabegron ErMirabegron14$8,558
Finasteride415$4,823
Methenamine Hippurate67$4,306
Potassium Citrate ErPotassium Citrate38$4,155
Testosterone38$4,023
Oxybutynin Chloride ErOxybutynin Chloride120$3,432
Estradiol44$2,931
Trospium Chloride44$2,517
Tadalafil11$2,362
Tolterodine Tartrate ErTolterodine Tartrate27$2,062
Alfuzosin Hcl ErAlfuzosin Hcl89$1,520

Paid to pharmacies, not to this prescriber.

Other surgical in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →